Gottschalk S - Search Results

1

Rewriting History: Epigenetic Reprogramming of CD8⁺ T Cell Differentiation to Enhance Immunotherapy.

Zebley CC, Gottschalk S, Youngblood B. Zebley CC, et al. Among authors: gottschalk s. Trends Immunol. 2020 Aug;41(8):665-675. doi: 10.1016/j.it.2020.06.008. Epub 2020 Jul 2. Trends Immunol. 2020. PMID: 32624330 Free PMC article. Review.

2

Adoptive T-Cell Immunotherapy.

Gottschalk S, Rooney CM. Gottschalk S, et al. Curr Top Microbiol Immunol. 2015;391:427-54. doi: 10.1007/978-3-319-22834-1_15. Curr Top Microbiol Immunol. 2015. PMID: 26428384 Free PMC article. Review.

3

Advances in immunotherapy for pediatric acute myeloid leukemia.

Bonifant CL, Velasquez MP, Gottschalk S. Bonifant CL, et al. Among authors: gottschalk s. Expert Opin Biol Ther. 2018 Jan;18(1):51-63. doi: 10.1080/14712598.2018.1384463. Epub 2017 Oct 11. Expert Opin Biol Ther. 2018. PMID: 28945115 Review.

4

Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.

Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S. Kalra M, et al. Among authors: gottschalk s. Cytotherapy. 2019 Feb;21(2):212-223. doi: 10.1016/j.jcyt.2018.08.001. Epub 2018 Nov 2. Cytotherapy. 2019. PMID: 30396848 Free PMC article.

5

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.

Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. Parihar R, et al. Among authors: gottschalk sm. Cancer Immunol Res. 2019 Mar;7(3):363-375. doi: 10.1158/2326-6066.CIR-18-0572. Epub 2019 Jan 16. Cancer Immunol Res. 2019. PMID: 30651290 Free PMC article.

6

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors.

DeRenzo C, Gottschalk S. DeRenzo C, et al. Among authors: gottschalk s. Front Immunol. 2019 Feb 15;10:218. doi: 10.3389/fimmu.2019.00218. eCollection 2019. Front Immunol. 2019. PMID: 30828333 Free PMC article. Review.

7

Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.

DeRenzo C, Gottschalk S. DeRenzo C, et al. Among authors: gottschalk s. Adv Exp Med Biol. 2020;1257:109-131. doi: 10.1007/978-3-030-43032-0_10. Adv Exp Med Biol. 2020. PMID: 32483735 Free PMC article. Review.

8

Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours.

Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Hsu K, et al. Among authors: gottschalk s. Cancer Gene Ther. 2021 Apr;28(3-4):321-334. doi: 10.1038/s41417-020-00221-4. Epub 2020 Sep 1. Cancer Gene Ther. 2021. PMID: 32873870 Free PMC article.

9

MyD88/CD40 signaling retains CAR T cells in a less differentiated state.

Prinzing B, Schreiner P, Bell M, Fan Y, Krenciute G, Gottschalk S. Prinzing B, et al. Among authors: gottschalk s. JCI Insight. 2020 Nov 5;5(21):e136093. doi: 10.1172/jci.insight.136093. JCI Insight. 2020. PMID: 33148882 Free PMC article.

10

Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin.

Wagner J, Wickman E, Shaw TI, Anido AA, Langfitt D, Zhang J, Porter SN, Pruett-Miller SM, Tillman H, Krenciute G, Gottschalk S. Wagner J, et al. Among authors: gottschalk s. Cancer Immunol Res. 2021 Mar;9(3):279-290. doi: 10.1158/2326-6066.CIR-20-0280. Epub 2020 Dec 22. Cancer Immunol Res. 2021. PMID: 33355188 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

389 results

Search Page

Filters